ApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice

Molecular Neurodegeneration

Volumn 8, Issue 1, 2013, Pages

  Liraz, Ori ^a   Boehm Cagan, Anat ^a   Michaelson, Daniel M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BLOOD LEVEL; CONTROLLED STUDY; HIPPOCAMPUS; MITOCHONDRION; MOUSE; NERVE CELL; NONHUMAN; PERIKARYON; PRESYNAPTIC NERVE; PROTEIN PHOSPHORYLATION;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEIN E4; BEHAVIOR, ANIMAL; COGNITION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC PREDISPOSITION TO DISEASE; HIPPOCAMPUS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; NEURONS; PHOSPHORYLATION; TAU PROTEINS; VESICULAR GLUTAMATE TRANSPORT PROTEINS;

MUS;

EID: 84877792642     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-8-16     Document Type: Article

References (104)

1. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde" Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR, Clin Anat 1995 8 429 431 10.1002/ca.980080612 8713166
2. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. Tesseur I, Zou K, Esposito L, Bard F, Berber E, Can JV, Lin AH, Crews L, Tremblay P, Mathews P, J Clin Invest 2006 116 3060 3069 10.1172/JCI27341 17080199 (Pubitemid 44684491)
3. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K, Proc Natl Acad Sci U S A 1985 82 4245 4249 10.1073/pnas.82.12.4245 3159021 (Pubitemid 15053619)
4. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Glenner GG, Wong CW, Biochem Biophys Res Commun 1984 122 1131 1135 10.1016/0006-291X(84)91209-9 6236805 (Pubitemid 14027629)
5. Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. Glabe CC, Subcell Biochem 2005 38 167 177 10.1007/0-387-23226-5-8 15709478
6. Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. King ME, Kan HM, Baas PW, Erisir A, Glabe CG, Bloom GS, J Cell Biol 2006 175 541 546 10.1083/jcb.200605187 17101697 (Pubitemid 44790607)
7. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E, Acta Neuropathol 2010 119 523 541 10.1007/s00401-010-0679-9 20354705
8. Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. O'Dwyer L, Lamberton F, Matura S, Tanner C, Scheibe M, Miller J, Rujescu D, Prvulovic D, Hampel H, PLoS One 2012 7 48895 10.1371/journal.pone.0048895 23152815
9. Neurodegenerative tauopathies. Lee VM, Goedert M, Trojanowski JQ, Annu Rev Neurosci 2001 24 1121 1159 10.1146/annurev.neuro.24.1.1121 11520930 (Pubitemid 32695256)
10. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E, Neurobiol Aging 2003 24 1079 1085 10.1016/j.neurobiolaging.2003.04.007 14643379 (Pubitemid 37487885)
11. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR, Brain Res Brain Res Rev 2000 33 95 130 10.1016/S0165-0173(00)00019-9 10967355
12. Possible role of tau in mediating pathological effects of apoE4 in vivo prior to and following activation of the amyloid cascade. Inbar D, Belinson H, Rosenman H, Michaelson DM, Neurodegener Dis 2010 7 16 23 10.1159/000283477 20160452
13. Neuropathological stageing of Alzheimer-related changes. Braak H, Braak E, Acta Neuropathol 1991 82 239 259 10.1007/BF00308809 1759558
14. The clinical use of structural MRI in Alzheimer disease. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM, Nat Rev Neurol 2010 6 67 77 10.1038/nrneurol.2009.215 20139996
15. Amyloid PET in Alzheimer research. Ishii K, Brain Nerve 2010 62 757 767 20675880
16. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ, J Alzheimers Dis 2010 20 843 854 20182025
17. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Rusinek H, De Santi S, Frid D, Tsui WH, Tarshish CY, Convit A, de Leon MJ, Radiology 2003 229 691 696 10.1148/radiol.2293021299 14657306 (Pubitemid 37467570)
18. Neuronal death: where does the end begin? Conforti L, Adalbert R, Coleman MP, Trends Neurosci 2007 30 159 166 10.1016/j.tins.2007.02.004 17339056 (Pubitemid 46505033)
19. Mechanisms of synaptic pathology in Alzheimer's disease. Masliah E, J Neural Transm Suppl 1998 53 147 158 10.1007/978-3-7091-6467-9-13 9700653 (Pubitemid 28361776)
20. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Scheff SW, DeKosky ST, Price DA, Neurobiol Aging 1990 11 29 37 10.1016/0197-4580(90)90059-9 2325814 (Pubitemid 20097857)
21. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA, Science 1993 261 921 923 10.1126/science.8346443 8346443 (Pubitemid 23275809)
22. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Roses AD, Annu Rev Med 1996 47 387 400 10.1146/annurev.med.47.1.387 8712790 (Pubitemid 26138899)
23. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Neurology 1993 43 1467 1472 10.1212/WNL.43.8.1467 8350998 (Pubitemid 23230526)
24. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. Mori E, Lee K, Yasuda M, Hashimoto M, Kazui H, Hirono N, Matsui M, Ann Neurol 2002 51 209 214 10.1002/ana.10093 11835377 (Pubitemid 34111443)
25. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD, Proc Natl Acad Sci U S A 1993 90 9649 9653 10.1073/pnas.90.20.9649 8415756 (Pubitemid 23315843)
26. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, Jakes R, Huang DY, Pericak-Vance M, Schmechel D, Roses AD, Proc Natl Acad Sci U S A 1994 91 11183 11186 10.1073/pnas.91.23.11183 7972031 (Pubitemid 24349650)
27. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Biol Psychiatry 2004 56 670 676 10.1016/j.biopsych.2004.07.021 15522251 (Pubitemid 39446849)
28. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. Arendt T, Schindler C, Bruckner MK, Eschrich K, Bigl V, Zedlick D, Marcova L, J Neurosci 1997 17 516 529 8987775 (Pubitemid 27024565)
29. Microglial activation in Alzheimer disease: Association with APOE genotype. Egensperger R, Kosel S, von Eitzen U, Graeber MB, Brain Pathol 1998 8 439 447 9669695 (Pubitemid 28308843)
30. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Proc Natl Acad Sci U S A 2009 106 6820 6825 10.1073/pnas.0900345106 19346482
31. The APOE varepsilon4 allele modulates brain white matter integrity in healthy adults. Heise V, Filippini N, Ebmeier KP, Mackay CE, Mol Psychiatry 2010 16 908 916 20820167
32. Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. Belinson H, Lev D, Masliah E, Michaelson DM, J Neurosci 2008 28 4690 4701 10.1523/JNEUROSCI.5633-07.2008 18448646
33. ApoE4-dependent Abeta-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum. Belinson H, Michaelson DM, J Neural Transm 2009 116 1427 1434 10.1007/s00702-009-0218-9 19370389
34. Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology. Hartman RE, Wozniak DF, Nardi A, Olney JW, Sartorius L, Holtzman DM, Exp Neurol 2001 170 326 344 10.1006/exnr.2001.7715 11476599 (Pubitemid 32758686)
35. Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. Manelli AM, Bulfinch LC, Sullivan PM, LaDu MJ, Neurobiol Aging 2007 28 1139 1147 10.1016/j.neurobiolaging.2006.05.024 16837105 (Pubitemid 46810054)
36. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Ye S, Huang Y, Mullendorff K, Dong L, Giedt G, Meng EC, Cohen FE, Kuntz ID, Weisgraber KH, Mahley RW, Proc Natl Acad Sci U S A 2005 102 18700 18705 10.1073/pnas.0508693102 16344478 (Pubitemid 43011289)
37. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Hardy J, Curr Alzheimer Res 2006 3 71 73 10.2174/156720506775697098 16472206
38. In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. Holtzman DM, J Mol Neurosci 2004 23 247 254 10.1385/JMN:23:3:247 15181253
39. Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Buttini M, Akeefe H, Lin C, Mahley RW, Pitas RE, Wyss-Coray T, Mucke L, Neuroscience 2000 97 207 210 10.1016/S0306-4522(00)00069-5 10799751 (Pubitemid 30224757)
40. Alzheimer's disease: genes, proteins, and therapy. Selkoe DJ, Physiol Rev 2001 81 741 766 11274343 (Pubitemid 32267077)
41. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE, Science 1994 264 850 852 10.1126/science.8171342 8171342 (Pubitemid 24193454)
42. Differences in apolipoprotein E3/3 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease. Xu PT, Li YJ, Qin XJ, Scherzer CR, Xu H, Schmechel DE, Hulette CM, Ervin J, Gullans SR, Haines J, Neurobiol Dis 2006 21 256 275 10.1016/j.nbd.2005.07.004 16198584 (Pubitemid 43099851)
43. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, Xu Q, Dee Fish J, Wyss-Coray T, Buttini M, Mucke L, J Neurosci 2004 24 2527 2534 10.1523/JNEUROSCI.4315-03.2004 15014128 (Pubitemid 38327965)
44. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, Van Leuven F, Am J Pathol 2000 156 951 964 10.1016/S0002-9440(10)64963-2 10702411 (Pubitemid 30626953)
45. Mitochondria take center stage in aging and neurodegeneration. Beal MF, Ann Neurol 2005 58 495 505 10.1002/ana.20624 16178023 (Pubitemid 41377212)
46. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene. Valla J, Yaari R, Wolf AB, Kusne Y, Beach TG, Roher AE, Corneveaux JJ, Huentelman MJ, Caselli RJ, Reiman EM, J Alzheimers Dis 2010 22 307 313 20847408
47. Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. Chen HK, Ji ZS, Dodson SE, Miranda RD, Rosenblum CI, Reynolds IJ, Freedman SB, Weisgraber KH, Huang Y, Mahley RW, J Biol Chem 2010 286 5215 5221 21118811
48. Functional analysis of APOE locus genetic variation implicates regional enhancers in the regulation of both TOMM40 and APOE. Bekris LM, Lutz F, Yu CE, J Hum Genet 2011 57 18 25 22089642
49. The role of apolipoprotein E in Alzheimer's disease. Kim J, Basak JM, Holtzman DM, Neuron 2009 63 287 303 10.1016/j.neuron.2009.06.026 19679070
50. Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. Andrews-Zwilling Y, Bien-Ly N, Xu Q, Li G, Bernardo A, Yoon SY, Zwilling D, Yan TX, Chen L, Huang Y, J Neurosci 2010 30 13707 13717 10.1523/JNEUROSCI.4040-10.2010 20943911
51. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N, J Biol Chem 1997 272 17972 17980 10.1074/jbc.272.29. 17972 9218423 (Pubitemid 27306374)
52. ApoE4 impairs hippocampal plasticity isoform-specifically and blocks the environmental stimulation of synaptogenesis and memory. Levi O, Jongen-Relo AL, Feldon J, Roses AD, Michaelson DM, Neurobiol Dis 2003 13 273 282 10.1016/S0969-9961(03)00045-7 12901842 (Pubitemid 36937209)
53. The Effects of Apolipoproteins E3 and E4 on the Transforming Growth Factor-beta System in Targeted Replacement Mice. Haas A, Liraz O, Michaelson DM, Neurodegener Dis 2012 10 41 45 10.1159/000334902 22301441
54. The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. Kariv-Inbal Z, Yacobson S, Berkecz R, Peter M, Janaky T, Lutjohann D, Broersen LM, Hartmann T, Michaelson DM, J Alzheimers Dis 2012 28 667 683 22057027
55. Changes in PKC gamma immunoreactivity in mouse hippocampus induced by spatial discrimination learning. Van der Zee EA, Compaan JC, de Boer M, Luiten PG, J Neurosci 1992 12 4808 4815 1464769
56. Quantitative analysis of GAD65 and GAD67 immunoreactivities in somata of GABAergic neurons in the mouse hippocampus proper (CA1 and CA3 regions), with special reference to parvalbumin-containing neurons. Fukuda T, Heizmann CW, Kosaka T, Brain Res 1997 764 237 243 10.1016/S0006-8993(97)00683-5 9295216 (Pubitemid 27380662)
57. Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-beta resulting in neurodegeneration. Belinson H, Kariv-Inbal Z, Kayed R, Masliah E, Michaelson DM, J Alzheimers Dis 2010 22 959 970 20858958
58. beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, Cell 1995 81 525 531 10.1016/0092-8674(95)90073-X 7758106
59. Molecular dissection of the paired helical filament. Goedert M, Spillantini MG, Jakes R, Crowther RA, Vanmechelen E, Probst A, Gotz J, Burki K, Cohen P, Neurobiol Aging 1995 16 325 334 10.1016/0197-4580(95)00017-9 7566342
60. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Zheng-Fischhofer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E, Eur J Biochem 1998 252 542 552 10.1046/j.1432-1327.1998.2520542.x 9546672 (Pubitemid 28156880)
61. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, Xu L, Aschmies S, Kirksey Y, Hu Y, J Neurosci 2008 28 11445 11453 10.1523/JNEUROSCI. 1972-08.2008 18987181
62. Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Sullivan PM, Han B, Liu F, Mace BE, Ervin JF, Wu S, Koger D, Paul S, Bales KR, Neurobiol Aging 2011 32 791 801 10.1016/j.neurobiolaging.2009.05.011 19577821
63. Spatial navigation in the Morris water maze: working and long lasting reference memories. Baldi E, Efoudebe M, Lorenzini CA, Bucherelli C, Neurosci Lett 2005 378 176 180 10.1016/j.neulet.2004.12.029 15781154 (Pubitemid 40386867)
64. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Chen Y, Durakoglugil MS, Xian X, Herz J, Proc Natl Acad Sci U S A 2010 107 12011 12016 10.1073/pnas.0914984107 20547867
65. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. Dumanis SB, Tesoriero JA, Babus LW, Nguyen MT, Trotter JH, Ladu MJ, Weeber EJ, Turner RS, Xu B, Rebeck GW, Hoe HS, J Neurosci 2009 29 15317 15322 10.1523/JNEUROSCI.4026-09.2009 19955384
66. Progressive loss of synaptic integrity in human apolipoprotein E4 targeted replacement mice and attenuation by apolipoprotein E2. Klein RC, Mace BE, Moore SD, Sullivan PM, Neuroscience 2010 171 1265 1272 10.1016/j. neuroscience.2010.10.027 20951774
67. ApoE isoform affects LTP in human targeted replacement mice. Trommer BL, Shah C, Yun SH, Gamkrelidze G, Pasternak ES, Ye GL, Sotak M, Sullivan PM, Pasternak JF, LaDu MJ, Neuroreport 2004 15 2655 2658 10.1097/00001756-200412030- 00020 15570172 (Pubitemid 40053957)
68. Apolipoprotein e and apolipoprotein e receptors: normal biology and roles in Alzheimer disease. Holtzman DM, Herz J, Bu G, Cold Spring Harb Perspect Med 2012 2 006312 10.1101/cshperspect.a006312 22393530
69. APOE genotype alters glial activation and loss of synaptic markers in mice. Zhu Y, Nwabuisi-Heath E, Dumanis SB, Tai LM, Yu C, Rebeck GW, Ladu MJ, Glia 2012 60 559 569 10.1002/glia.22289 22228589
70. Synaptic loss is accompanied by an increase in synaptic area in the dentate gyrus of aged human apolipoprotein E4 transgenic mice. Cambon K, Davies HA, Stewart MG, Neuroscience 2000 97 685 692 10.1016/S0306-4522(00)00065-8 10842013 (Pubitemid 30332175)
71. Genetic variation at a single locus and age of onset for Alzheimer's disease. Lutz MW, Crenshaw DG, Saunders AM, Roses AD, Alzheimers Dement 2010 6 125 131 10.1016/j.jalz.2010.01.011 20298972
72. Apolipoprotein E4 (1-272) fragment is associated with mitochondrial proteins and affects mitochondrial function in neuronal cells. Nakamura T, Watanabe A, Fujino T, Hosono T, Michikawa M, Mol Neurodegener 2009 4 35 10.1186/1750-1326-4-35 19695092
73. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM, Proc Natl Acad Sci U S A 2000 97 2892 2897 10.1073/pnas.050004797 10694577 (Pubitemid 30159268)
74. Phosphorylation state of tau in the hippocampus of apolipoprotein E4 and E3 knock-in mice. Kobayashi M, Ishiguro K, Katoh-Fukui Y, Yokoyama M, Fujita SC, Neuroreport 2003 14 699 702 10.1097/00001756-200304150-00008 12692466 (Pubitemid 36570925)
75. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Sci Transl Med 2011 3 89ra57 10.1126/scitranslmed.3002156 21715678
76. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV, J Clin Invest 2008 118 12 4002 4013 10.1172/JCI36663 19033669
77. ApoE promotes the proteolytic degradation of Abeta. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Neuron 2008 58 681 693 10.1016/j.neuron.2008.04.010 18549781 (Pubitemid 351778466)
78. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM, Nat Med 2004 10 719 726 10.1038/nm1058 15195085 (Pubitemid 38937637)
79. Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. Marzolo MP, Bu G, Semin Cell Dev Biol 2009 20 191 200 10.1016/j.semcdb.2008.10.005 19041409
80. Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease: a quantitative study of visual and auditory cortices. Lewis DA, Campbell MJ, Terry RD, Morrison JH, J Neurosci 1987 7 1799 1808 2439665 (Pubitemid 17119802)
81. Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex. Sokolow S, Luu SH, Nandy K, Miller CA, Vinters HV, Poon WW, Gylys KH, Neurobiol Dis 2012 45 381 387 10.1016/j.nbd.2011.08.027 21914482
82. APP processing and synaptic function. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R, Neuron 2003 37 925 937 10.1016/S0896-6273(03)00124-7 12670422 (Pubitemid 36398299)
83. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Strittmatter WJ, Weisgraber KH, Goedert M, Saunders AM, Huang D, Corder EH, Dong LM, Jakes R, Alberts MJ, Gilbert JR, Exp Neurol 1994 125 163 171 discussion 172-164 10.1006/exnr.1994.1019 8313935 (Pubitemid 24076094)
84. Apolipoprotein E and beta-amyloid (1-42) regulation of glycogen synthase kinase-3beta. Cedazo-Minguez A, Popescu BO, Blanco-Millan JM, Akterin S, Pei JJ, Winblad B, Cowburn RF, J Neurochem 2003 87 1152 1164 10.1046/j.1471-4159.2003. 02088.x 14622095 (Pubitemid 37492856)
85. Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc. Harris FM, Brecht WJ, Xu Q, Mahley RW, Huang Y, J Biol Chem 2004 279 44795 44801 10.1074/jbc.M408127200 15322121 (Pubitemid 39430890)
86. Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E. Leroy A, Landrieu I, Huvent I, Legrand D, Codeville B, Wieruszeski JM, Lippens G, J Biol Chem 2010 285 33435 33444 10.1074/jbc.M110.149419 20679343
87. Regulation of microtubule dynamics by microtubule-associated protein expression and phosphorylation during neuronal development. Avila J, Dominguez J, Diaz-Nido J, Int J Dev Biol 1994 38 13 25 8074993 (Pubitemid 24149303)
88. Differential phosphorylation of tau proteins during kitten brain development and Alzheimer's disease. Riederer BM, Mourton-Gilles C, Frey P, Delacourte A, Probst A, J Neurocytol 2001 30 145 158 10.1023/A:1011991207942 11577253 (Pubitemid 33078191)
89. Developmental expression of tau proteins in the chicken and rat brain: rapid down-regulation of a paired helical filament epitope in the rat cerebral cortex coincides with the transition from immature to adult tau isoforms. Rosner H, Rebhan M, Vacun G, Vanmechelen E, Int J Dev Neurosci 1995 13 607 617 10.1016/0736-5748(95)00042-F 8553895
90. Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. Tesseur I, Van Dorpe J, Bruynseels K, Bronfman F, Sciot R, Van Lommel A, Van Leuven F, Am J Pathol 2000 157 1495 1510 10.1016/S0002-9440(10)64788-8 11073810
91. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW, Proc Natl Acad Sci U S A 2001 98 8838 8843 10.1073/pnas.151254698 11447277 (Pubitemid 32678114)
92. ApoE epsilon4 is associated with eIF2alpha phosphorylation and impaired learning in young mice. Segev Y, Michaelson DM, Rosenblum K, Neurobiol Aging 2012
93. ApoE4-Driven Accumulation of Intraneuronal Oligomerized Abeta42 following Activation of the Amyloid Cascade In Vivo Is Mediated by a Gain of Function. Zepa L, Frenkel M, Belinson H, Kariv-Inbal Z, Kayed R, Masliah E, Michaelson DM, Int J Alzheimers Dis 2010 2011 792070
94. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Nature 2012 485 512 516 22622580
95. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M, J Biol Chem 2011 286 17536 17542 10.1074/jbc.M111.225532 21471207
96. A SAGE study of apolipoprotein E3/3, E3/4 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease. Xu PT, Li YJ, Qin XJ, Kroner C, Green-Odlum A, Xu H, Wang TY, Schmechel DE, Hulette CM, Ervin J, Mol Cell Neurosci 2007 36 313 331 10.1016/j.mcn.2007.06.009 17822919 (Pubitemid 47633197)
97. Cognitive function and apolipoprotein E in very old adults: findings from the Nun Study. Riley KP, Snowdon DA, Saunders AM, Roses AD, Mortimer JA, Nanayakkara N, J Gerontol B Psychol Sci Soc Sci 2000 55 69 75 10.1093/geronb/55.2.S69 10794191
98. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Proc Natl Acad Sci U S A 2000 97 6037 6042 10.1073/pnas.090106797 10811879 (Pubitemid 30367519)
99. Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer's disease as based on APOE genotype. Conejero-Goldberg C, Hyde TM, Chen S, Dreses-Werringloer U, Herman MM, Kleinman JE, Davies P, Goldberg TE, Mol Psychiatry 2011 16 836 847 10.1038/mp.2010.57 20479757
100. Positive effects of cholinergic stimulation favor young APOE epsilon4 carriers. Marchant NL, King SL, Tabet N, Rusted JM, Neuropsychopharmacology 2010 35 1090 1096 10.1038/npp.2009.214 20072115
101. APOE related alterations in cerebral activation even at college age. Scarmeas N, Habeck CG, Hilton J, Anderson KE, Flynn J, Park A, Stern Y, J Neurol Neurosurg Psychiatry 2005 76 1440 1444 10.1136/jnnp.2004.053645 16170092 (Pubitemid 41360988)
102. Knickmeyer RC, Wang J, Zhu H, Geng X, Woolson S, Hamer RM, Konneker T, Lin W, Styner M Gilmore JH: Common Variants in Psychiatric Risk Genes Predict Brain Structure at Birth. Cereb Cortex 2013
103. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Science 2012 335 1503 1506 10.1126/science.1217697 22323736
104. Counteracting the pathological effects of apoE4 in vivo with anti apoE4 mAbs. Michaelson DM, Ishai L, Ori L, Anat B, Alex N, ApoE, ApoE Receptors & Neurodegeneration Symposium; Mayo Clinic Jacksonville Florida 2012 23677929